# US 2023/0055008 A1 · Method for asymmetric amplification of target nucleic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055008 A1
- Document ID: US20230055008A1
- Status: Published application
- Kind: A1
- Application number: 17/757,986
- Filed: 2020-08-06
- Published: 2023-02-23
- Earliest claimed: 2019-12-26
- Assignees: Xiamen University
- Applicants: Xiamen University
- Inventors: Qiuying HUANG; Qingge LI
- Web page: https://patentgrep.com/patent/US20230055008A1

## CPC

- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6853: using modified primers or templates
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 2600/16: Primer sets for multiplex assays
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided is a method for multiplex and asymmetric amplification of one or more target nucleic acids in a sample. The method can simultaneously amplify multiple target nucleic acids existing in a sample, and can simultaneously produce a large number of single-chain products.

## Claims

### Claim 1

A method for amplifying one or more target nucleic acids in a sample, comprising:
(1) providing: (i) a sample containing one or more target nucleic acids; (ii) a universal primer; and (iii) a target-specific primer pair for each target nucleic acid to be amplified; wherein,
the universal primer comprises a first universal sequence;
the target-specific primer pair is capable of amplifying the target nucleic acid and comprises a forward primer and a reverse primer, wherein the forward primer comprises a second universal sequence and a forward nucleotide sequence specific to the target nucleic acid, and the forward nucleotide sequence is located at a 3′ end of the second universal sequence; the reverse primer comprises the first universal sequence and a reverse nucleotide sequence specific to the target nucleic acid, and the reverse nucleotide sequence is located at a 3′ end of the first universal sequence; and, under a condition allowing nucleic acid hybridization or annealing, the first universal sequence is capable of hybridizing or annealing to a complementary sequence of the second universal sequence, and there is a difference between the second universal sequence and the first universal sequence, and the difference comprises that one or more nucleotides located at the 3′ end of the first universal sequence are each independently deleted or substituted; and, the first universal sequence is not completely complementary to a complementary sequence of the forward primer; and
(2) amplifying the target nucleic acids in the sample through a PCR reaction using the universal primer and the target-specific primer pair under a condition that allows nucleic acid amplification.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method has one or more technical features selected from the following:
(1) the method is used to amplify 1-5, 5-10, 10-15, 15-20, 20-50 or more target nucleic acids;
(2) in step (1) of the method, 1-5, 5-10, 10-15, 15-20, 20-50 or more target-specific primer pairs are provided;
(3) in step (2) of the method, the universal primer has a working concentration higher than the working concentration of the forward primer and the reverse primer;
(4) in step (2) of the method, the forward primer and the reverse primer have the same or different working concentration;
(5) the sample or target nucleic acid comprises mRNA, and before performing step (2) of the method, a reverse transcription reaction is performed on the sample; and
(6) in step (2) of the method, a nucleic acid polymerase is used to perform the PCR reaction.

### Claim at position 3

-10. (canceled)

### Claim 11 (depends on 1)

The method according to claim 1, wherein the method has one or more technical features selected from the following:
(1) the universal primer has a working concentration 1-5 times, 5-10 times, 10-15 times, 15-20 times, 20-50 times or more times higher than the working concentration of the forward primer and the reverse primer;
(2) the nucleic acid polymerase is a template-dependent nucleic acid polymerase;
(3) the nucleic acid polymerase is a DNA polymerase;
(4) the nucleic acid polymerase is a thermostable DNA polymerase;
(5) the nucleic acid polymerase is obtained from Thermus aquaticus (Taq), Thermus thermophiles (Tth), Thermus filiformis, Thermis flavus, Thermococcus literalis, Thermus antranildanii, Thermus caldophllus, Thermus chliarophilus, Thermus flavus, Thermus igniterrae, Thermus lacteus, Thermus oshimai, Thermus ruber, Thermus rubens, Thermus scotoductus, Thermus silvanus, Thermus thermophllus, Thermotoga maritima, Thermotoga neapolitana, Thermosipho africanus, Thermococcus literalis, Thermococcus barossi, Thermococcus gorgonarius, Thermotoga maritima, Thermotoga neapolitana, Thermosiphoafricanus, Pyrococcus woesei, Pyrococcus horikoshii, Pyrococcus abyssi, Pyrodictium occultum, Aquifexpyrophilus and Aquifex aeolieus; and
(6) the nucleic acid polymerase is Taq polymerase.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the method has one or more technical features selected from the following:
(1) the universal primer consists of the first universal sequence, or, the universal primer comprises the first universal sequence and an additional sequence, wherein the additional sequence is located at a 5′ end of the first universal sequence;
(2) the first universal sequence is located in a 3′ portion of the universal primer;
(3) the universal primer has a length of 5-15 nt, 15-20 nt, 20-30 nt, 30-40 nt, or 40-50 nt;
(4) the universal primer or any component thereof comprises a naturally occurring nucleotide, a modified nucleotide, a non-natural nucleotide, or any combination thereof.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the method has one or more technical features selected from the following:
(1) in the forward primer, the forward nucleotide sequence is directly linked to the 3′ end of the second universal sequence, or the forward nucleotide sequence is linked to the 3′ end of the second universal sequence through a nucleotide linker;
(2) the forward primer further comprises an additional sequence, which is located at a 5′ end of the second universal sequence;
(3) the forward primer comprises the second universal sequence and a forward nucleotide sequence from 5′ to 3′; or, the forward primer comprises the second universal sequence, a nucleotide linker and a forward nucleotide sequence from 5′ to 3′; or, the forward primer comprises an additional sequence, the second universal sequence and a forward nucleotide sequence from 5′ to 3′; or, the forward primer comprises an additional sequence, the second universal sequence, a nucleotide linker and a forward nucleotide sequence from 5′ to 3′;
(4) the forward nucleotide sequence is located in a 3′ portion of the forward primer;
(5) the forward nucleotide sequence has a length of 10-20 nt, 20-30 nt, 30-40 nt, 40-50 nt, 50-60 nt, 60-70 nt, 70-80 nt, 80-90 nt, or 90-100 nt;
(6) the forward primer has a length of 15-20 nt, 20-30 nt, 30-40 nt, 40-50 nt, 50-60 nt, 60-70 nt, 70-80 nt, 80-90 nt, 90-100 nt, 100-110 nt, 110-120 nt, 120-130 nt, 130-140 nt, or 140-150 nt;
(7) the forward primer or any component thereof comprises a naturally occurring nucleotide, a modified nucleotide, a non-natural nucleotide, or any combination thereof;
(8) in the reverse primer, the reverse nucleotide sequence is directly linked to the 3′ end of the first universal sequence, or the reverse nucleotide sequence is linked to the 3′ end of the first universal sequence through a nucleotide linker;
(9) the reverse primer further comprises an additional sequence, which is located at a 5′ end of the first universal sequence;
(10) the reverse primer comprises the first universal sequence and a reverse nucleotide sequence from 5′ to 3′; or, the reverse primer comprises the first universal sequence, a nucleotide linker and a reverse nucleotide sequence from 5′ to 3′; or, the reverse primer comprises an additional sequence, the first universal sequence, and a reverse nucleotide sequence from 5′ to 3′; or, the reverse primer comprises an additional sequence, the first universal sequence, a nucleotide linker and a reverse nucleotide sequence from 5′ to 3′;
(11) the reverse nucleotide sequence is located in a 3′ portion of the reverse primer;
(12) the reverse nucleotide sequence has a length of 10-20 nt, 20-30 nt, 30-40 nt, 40-50 nt, 50-60 nt, 60-70 nt, 70-80 nt, 80-90nt, or 90-100nt;
(13) the reverse primer has a length of 15-20 nt, 20-30 nt, 30-40 nt, 40-50 nt, 50-60 nt, 60-70 nt, 70-80 nt, 80-90 nt, 90-100 nt, 100-110 nt, 110-120 nt, 120-130 nt, 130-140 nt, or 140-150 nt;
(14) the reverse primer or any component thereof comprises a naturally occurring nucleotide, a modified nucleotide, a non-natural nucleotide, or any combination thereof;
(15) at least one nucleotide at the 3′ end of the first universal sequence is not complementary to a complementary sequence of the forward primer;
(16) 1-5, 5-10, 10-15, 15-20 or more nucleotides at the 3′ end of the first universal sequence is not complementary to a complementary sequence of the forward primer; and
(17) the difference between the second universal sequence and the first universal sequence comprises 1-5, 5-10, 10-15, 15-20 or more nucleotides at the 3′ end of the first universal sequence, wherein each nucleotide is independently deleted or substituted.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the method has one or more technical features selected from the following:
(1) the sample contains DNA, RNA, or any combination thereof;
(2) the target nucleic acid to be amplified is DNA, RNA, or any combination thereof;
(3) the target nucleic acid to be amplified is single-stranded or double-stranded; and
(4) the sample or target nucleic acid is obtained from a prokaryote, a eukaryote, a virus, or a viroid.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the method has one or more technical features selected from the following:
(1) said DNA is a genomic DNA or cDNA;
(2) said RNA is a mRNA;
(3) the eukaryote is selected from a protozoan, parasite, fungus, yeast, plant, and animal;
(4) the eukaryote is a mammal;
(5) the eukaryote is a human; and
(6) the virus is selected from Herpes virus, HIV, influenza virus, EB virus, hepatitis virus, and polio virus.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the steps (1) to (2) of the method are carried out by a protocol comprising the following steps (a) to (f):
(a) providing: (i) the sample containing the one or more target nucleic acids; (ii) the universal primer; and (iii) the target-specific primer pair for each nuclei acid to be amplified;
(b) mixing the sample with the universal primer and the target-specific primer pair, and a nucleic acid polymerase;
(c) incubating the product of the previous step under a condition that allow nucleic acid denaturation;
(d) incubating the product of the previous step under a condition that allow nucleic acid annealing or hybridization;
(e) incubating the product of the previous step under a condition that allow nucleic acid extension; and
(f) optionally, repeating steps (c) to (e) one or more times.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the method has one or more technical features selected from the following:
(1) in step (c), incubating the product of step (b) at a temperature of 80-105° C., thereby allowing the nucleic acid denaturation;
(2) in step (c), incubating the product of step (b) for 10-20 s, 20-40 s, 40-60 s, 1-2 min, or 2-5 min;
(3) in step (d), incubating the product of step (c) at a temperature of 35-40° C., 40-45° C., 45-50° C., 50-55° C., 55-60° C., 60-65° C., or 65-70° C., thereby allowing the nucleic acid annealing or hybridization;
(4) in step (d), incubating the product of step (c) for 10-20 s, 20-40 s, 40-60 s, 1-2 min, or 2-5 min;
(5) in step (e), incubating the product of step (d) at a temperature of 35-40° C., 40-45° C., 45-50° C., 50-55° C., 55-60° C., 60-65° C., 65-70° C., 70-75° C., 75-80° C., 80-85° C., thereby allowing the nucleic acid extension;
(6) in step (e), incubating the product of step (d) for 10-20 s, 20-40 s, 40-60 s, 1-2 min, 2-5 min, 5-10 min, 10-20 min or 20-30 min;
(7) performing steps (d) and (e) at the same or different temperatures; and
(8) repeating steps (c) to (e) at least once; optionally, when repeating steps (c) to (e) one or more times, the conditions used in steps (c) to (e) of each cycle are independently the same or different.

### Claim 18 (depends on 1)

A method for detecting one or more target nucleic acids in a sample, comprising: (i) using the method according to claim 1 to amplify the one or more target nucleic acids in the sample; and (ii) performing melting curve analysis on the product of step (i).

### Claim 19 (depends on 18)

The method according to claim 18, wherein the method comprises the steps of:
(1) providing: (i) a sample containing one or more target nucleic acids; (ii) a universal primer; and (iii) a target-specific primer pair and a detection probe for each target nucleic acid to be amplified; wherein,
the universal primer comprises a first universal sequence;
the target-specific primer pair is capable of amplifying the target nucleic acid and comprises a forward primer and a reverse primer, wherein the forward primer comprises a second universal sequence and a forward nucleotide sequence specific to the target nucleic acid, and the forward nucleotide sequence is located at a 3′ end of the second universal sequence; the reverse primer comprises the first universal sequence and a reverse nucleotide sequence specific to the target nucleic acid, and the reverse nucleotide sequence is located at a 3′ end of the first universal sequence; and, under a condition allowing nucleic acid hybridization or annealing, the first universal sequence is capable of hybridizing or annealing to a complementary sequence of the second universal sequence, and there is a difference between the second universal sequence and the first universal sequence, and the difference comprises that one or more nucleotides located at the 3′ end of the first universal sequence are each independently deleted or substituted; and, the first universal sequence is not completely complementary to a complementary sequence of the forward primer;
the detection probe comprises a probe nucleotide sequence specific to the target nucleic acid, and is labeled with a reporter group and a quencher group, wherein the reporter group is capable of emitting a signal, and the quencher group is capable of absorbing or quenching the signal emitted by the reporter group; and the signal emitted by the detection probe when it hybridizes to its complementary sequence is different from the signal emitted when it is not hybridized to its complementary sequence;
(2) amplifying the target nucleic acids in the sample through a PCR reaction by using the universal primer and the target-specific primer pair under a condition that allows nucleic acid amplification; and
(3) performing melting curve analysis on the product in step (2) using the detection probe; and determining whether the target nucleic acid exists in the sample according to the result of the melting curve analysis.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the method has one or more technical features selected from the following:
(1) the universal primer consists of the first universal sequence, or, the universal primer comprises the first universal sequence and an additional sequence, wherein the additional sequence is located at a 5′ end of the first universal sequence;
(2) the first universal sequence is located in a 3′ portion of the universal primer;
(3) in the forward primer, the forward nucleotide sequence is directly linked to the 3′ end of the second universal sequence, or the forward nucleotide sequence is linked to the 3′ end of the second universal sequence through a nucleotide linker;
(4) the forward primer further comprises an additional sequence, which is located at a 5′ end of the second universal sequence;
(5) the forward primer comprises the second universal sequence and a forward nucleotide sequence from 5′ to 3′; or, the forward primer comprises the second universal sequence, a nucleotide linker and a forward nucleotide sequence from 5′ to 3′; or, the forward primer comprises an additional sequence, the second universal sequence and a forward nucleotide sequence from 5′ to 3′; or, the forward primer comprises an additional sequence, the second universal sequence, a nucleotide linker and a forward nucleotide sequence from 5′ to 3′;
(6) the forward nucleotide sequence is located in a 3′ portion of the forward primer;
(7) in the reverse primer, the reverse nucleotide sequence is directly linked to the 3′ end of the first universal sequence, or the reverse nucleotide sequence is linked to the 3′ end of the first universal sequence through a nucleotide linker;
(8) the reverse primer further comprises an additional sequence, which is located at a 5′ end of the first universal sequence;
(9) the reverse primer comprises the first universal sequence and a reverse nucleotide sequence from 5′ to 3′; or, the reverse primer comprises the first universal sequence, a nucleotide linker and a reverse nucleotide sequence from 5′ to 3′; or, the reverse primer comprises an additional sequence, the first universal sequence, and a reverse nucleotide sequence from 5′ to 3′; or, the reverse primer comprises an additional sequence, the first universal sequence, a nucleotide linker and a reverse nucleotide sequence from 5′ to 3′;
(10) the reverse nucleotide sequence is located in a 3′ portion of the reverse primer; and
(11) at least one nucleotide at the 3′ end of the first universal sequence is not complementary to a complementary sequence of the forward primer; and
(12) 1-5, 5-10, 10-15, 15-20 or more nucleotides at the 3′ end of the first universal sequence is not complementary to a complementary sequence of the forward primer.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the method has one or more technical features selected from the following:
(1) in step (2), the sample is mixed with the universal primer, the target-specific primer pair, and the nucleic acid polymerase, and the PCR reaction is performed, and then, after the PCR reaction is completed, the detection probe is added to the product of step (2), and the melting curve analysis is performed; or, in step (2), the sample is mixed with the universal primer, the target-specific primer pair and the detection probe, and the nucleic acid polymerase, and the PCR reaction is performed, and then, after the PCR reaction is completed, the melting curve analysis is performed;
(2) the detection probe comprises a naturally occurring nucleotide, a modified nucleotide, a non-natural nucleotide, or any combination thereof;
(3) the detection probe has a length of 15-20 nt, 20-30 nt, 30-40 nt, 40-50 nt, 50-60 nt, 60-70 nt, 70-80 nt, 80-90 nt, 90-100 nt, 100-200 nt, 200-300 nt, 300-400 nt, 400-500 nt, 500-600 nt, 600-700 nt, 700-800 nt, 800-900 nt, or 900-1000 nt;
(4) the detection probe has a 3′-OH terminus; or, a 3′-terminus of the detection probe is blocked;
(5) the detection probe is a self-quenched probe;
(6) the reporter group in the detection probe is a fluorescent group; and the quencher group is a molecule or group capable of absorbing/quenching the fluorescence;
(7) the detection probe has a resistance against nuclease activity;
(8) the detection probe is linear or has a hairpin structure;
(9) each of the detection probes independently has the same or different reporter group;
(10) in step (3), the product in step (2) is gradually heated or cooled and the signal emitted by the reporter group on each detection probe is monitored in real time, so as to obtain a curve of signal intensity of each reporter group that varies with the change of temperature; then, the curve is differentiated to obtain a melting curve of the product in step (2); and
(11) the presence of the target nucleic acid corresponding to the melting peak (melting point) is determined according to the melting peak (melting point) in the melting curve.

### Claim 22 (depends on 19)

The method according to claim 19, wherein steps (1) to (3) of the method are carried out by a protocol comprising the following steps (a) to (g):
(a) providing: (i) the sample containing one or more target nucleic acids; (ii) the universal primer ; and (iii) the target-specific primer pair and the detection probe for each target nucleic acid to be amplified;
(b) mixing the sample with the universal primer, the target-specific primer pair and the detection probe, and a nucleic acid polymerase;
(c) incubating the product of the previous step under a condition that allow nucleic acid denaturation;
(d) incubating the product of the previous step under a condition that allow nucleic acid annealing or hybridization;
(e) incubating the product of the previous step under a condition that allow nucleic acid extension;
(f) optionally, repeating steps (c) to (e) once or more times; and
(g) performing melting curve analysis on the product of the previous step

### Claim 23 (depends on 21)

The method according to claim 21, wherein the method has one or more technical features selected from the following:
(1) the naturally occurring nucleotide is a deoxyribonucleotide or a ribonucleotide;
(2) the non-natural nucleotide is a peptide nucleic acid (PNA) or a locked nucleic acid;
(3) the 3′-terminus of the detection probe is blocked by adding a chemical moiety to the 3′-OH of the last nucleotide of the detection probe, by removing the 3′-OH of the last nucleotide of the detection probe, or by replacing the last nucleotide with a dideoxynucleotide;
(4) the 3′-terminus of the detection probe is blocked by adding a biotin or an alkyl to a 3′-OH of the last nucleotide of the detection probe;
(5) the reporter group and the quencher group are separated by a distance of 10-80 nt or more;
(6) the reporter group is selected from ALEX-350, FAM, VIC, TET, CAL Fluor® Gold 540, JOE, HEX, CAL Fluor Orange 560, TAMRA, CAL Fluor Red 590, ROX, CAL Fluor Red 610, TEXAS RED, CAL Fluor Red 635, Quasar 670, CY3, CY5, CY5.5, Quasar 705, and combination thereof;
(7) the quencher group is selected from DABCYL, BHQ, ECLIPSE, TAMRA, and combination thereof;
(8) the detection probe has a resistance against 5′ nuclease activity;
(9) the detection probe has a resistance against 5′ to 3′ exonuclease activity;
(10) the detection probe has a backbone comprising a modification for resisting nuclease activity;
(11) the detection probe has a backbone comprising a modification selected from phosphorothioate ester bond, alkyl phosphotriester bond, aryl phosphotriester bond, alkyl phosphonate ester bond, aryl phosphonate ester bond, hydrogenated phosphate ester bond, alkyl phosphoramidate ester bond, aryl phosphoramidate ester bond, 2′-O-aminopropyl modification, 2′-O-alkyl modification, 2′-O-allyl modification, 2′-O-butyl modification, and 1-(4′-thio-PD-ribofuranosyl) modification;
(12) the detection probe is labeled with a reporter group at its 5′ end or upstream and labeled with a quencher group at its 3′ end or downstream, or labeled with a reporter group at its 3′ end or downstream and labeled with a quencher group at its 5′ end or upstream; and
(13) the detection probes have the same reporter group, and the product in step (2) is subjected to melting curve analysis, and then the presence of the target nucleic acid is determined according to the melting peak in the melting curve; or, the detection probes have different reporter groups, and the product in step (2) is subjected to melting curve analysis, and then the presence of the target nucleic acid is determined according to the signal type of the reporter group and the melting peak in the melting curve.

### Claim 24

A primer set, which comprises: a universal primer, and, one or more target-specific primer pairs; wherein,
the universal primer comprises a first universal sequence;
each target-specific primer pair is capable of amplifying a target nucleic acid and comprises a forward primer and a reverse primer, wherein the forward primer comprises a second universal sequence and a forward nucleotide sequence specific to the target nucleic acid, and the forward nucleotide sequence is located at a 3′ end of the second universal sequence; the reverse primer comprises the first universal sequence and a reverse nucleotide sequence specific to the target nucleic acid, and the reverse nucleotide sequence is located at a 3′ end of the first universal sequence; and, under a condition that allows nucleic acid hybridization or annealing, the first universal sequence is capable of hybridizing or annealing to a complementary sequence of the second universal sequence, and there is a difference between the second universal sequence and the first universal sequence, and the difference comprises that one or more nucleotides located at the 3′ end of the first universal sequence are each independently deleted or substituted; and, the first universal sequence is not completely complementary to a complementary sequence of the forward primer.

### Claim 25 (depends on 24)

The primer set according to claim 24, wherein the primer set has one or more technical features selected from the following:
(1) the universal primer consists of the first universal sequence, or, the universal primer comprises the first universal sequence and an additional sequence, and the additional sequence is located at a 5′ end of the first universal sequence;
(2) the first universal sequence is located in a 3′ portion of the universal primer;
(3) in the forward primer, the forward nucleotide sequence is directly linked to the 3′ end of the second universal sequence, or the forward nucleotide sequence is linked to the 3′ end of the second universal sequence through a nucleotide linker;
(4) the forward primer further comprises an additional sequence, which is located at a 5′ end of the second universal sequence;
(5) the forward primer comprises the second universal sequence and a forward nucleotide sequence from 5′ to 3′; or, the forward primer comprises the second universal sequence, a nucleotide linker and a forward nucleotide sequence from 5′ to 3′; or, the forward primer comprises an additional sequence, the second universal sequence and a forward nucleotide sequence from 5′ to 3′; or, the forward primer comprises an additional sequence, the second universal sequence, a nucleotide linker and a forward nucleotide sequence from 5′ to 3′;
(6) the forward nucleotide sequence is located in a 3′ portion of the forward primer;
(7) in the reverse primer, the reverse nucleotide sequence is directly linked to the 3′ end of the first universal sequence, or the reverse nucleotide sequence is linked to the 3′ end of the first universal sequence through a nucleotide linker;
(8) the reverse primer further comprises an additional sequence, which is located at a 5′ end of the first universal sequence;
(9) the reverse primer comprises the first universal sequence and a reverse nucleotide sequence from 5′ to 3′; or, the reverse primer comprises the first universal sequence, a nucleotide linker and a reverse nucleotide sequence from 5′ to 3′; or, the reverse primer comprises an additional sequence, the first universal sequence, and a reverse nucleotide sequence from 5′ to 3′; or, the reverse primer comprises an additional sequence, the first universal sequence, a nucleotide linker and a reverse nucleotide sequence from 5′ to 3′;
(10) the reverse nucleotide sequence is located in a 3′ portion of the reverse primer;
(11) at least one nucleotide at the 3′ end of the first universal sequence is not complementary to a complementary sequence of the forward primer;
(12) 1-5, 5-10, 10-15, 15-20 or more nucleotides at the 3′ end of the first universal sequence is not complementary to a complementary sequence of the forward primer; and
(13) the primer set comprises 1-5, 5-10, 10-15, 15-20, 20-50 or more target-specific primer pairs.

### Claim 26 (depends on 24)

A kit comprising the primer set according to claim 24, and one or more components selected from the following: a nucleic acid polymerase, a reagent for carrying out nucleic acid amplification, a reagent for carrying out sequencing, a reagent for gene chip detection, a reagent for melting curve analysis, or any combination thereof.

### Claim 27 (depends on 26)

The kit according to claim 26, wherein the kit has one or more technical features selected from the following:
(1) the nucleic acid polymerase is a template-dependent nucleic acid polymerase;
(2) the reagent for nucleic acid amplification comprises a working buffer for enzyme, dNTPs, water, a solution containing ion, a single-stranded DNA-binding protein, or any combination thereof;
(3) the reagent for sequencing comprises a working buffer for enzyme, dNTPs, ddNTPs, water, a solution containing ion, a single-strand DNA-binding protein (SSB), a ligase, a nucleic acid linker, a sequencing primer, or any combination thereof;
(4) the reagent for gene chip detection comprises a working buffer for enzyme, dNTPs, water, a hybridization buffer, a washing buffer, a labeling reagent, or any combination thereof; and
(5) the reagent for melting curve analysis comprises a detection probe.
